Sensitivity and specificity values ​​for invasive melanoma were 95% and 85%, and 100% and 93%, respectively.

stockholm, March 6, 2024 /PRNewswire/ — Results from a prospective, peer-reviewed, multicenter clinical trial were announced today. British Society of Dermatology Journal Link to article We showed that AI can help significantly improve melanoma detection rates.

The trial, conducted in 37 primary care facilities in Sweden, was designed to evaluate Dermalyser, a smartphone-based diagnostic decision support system that leverages advanced artificial intelligence (AI).

228 patients who were examined in primary care and showed skin lesions that raised concerns of melanoma by their doctors also underwent additional evaluation using a smartphone with a dermatoscope placed in front of a camera (dermalizer). received. Of the 253 lesions of concern identified, 21 were found to be melanomas, 11 were invasive melanomas, and 10 were melanomas in situ (precancerous melanocytic lesions).

Area under receiver operating characteristic (AUROC) curves were generated to evaluate the accuracy of the dermalyzer in identifying melanoma.for invasive melanoma AUROC ranged from 0.965 to 0.997, corresponding to maximum sensitivity and specificity of 100% and 92.6%, respectively. When including in situ melanoma, the AUROC was 0.960, and the maximum sensitivity and specificity were 95.2% and 84.5%, respectively.

magnus forkAssociate Professor and Chief Researcher of General Practice, Linköping University Faculty of Health, Medical and Care Sciences Comment: “The clinical decision support tool evaluated in this study demonstrated high diagnostic accuracy when used prospectively in primary care patients. In addition, healthcare professionals involved in this study indicated that they had a high level of confidence in dermalyzers, and that dermalyzers could easily be incorporated into current clinical routines. This strongly suggests that it can be incorporated into

Christopher Ekström, AI Medical Technology CEO It added: “We believe this trial conclusively proves that the use of AI has the potential to revolutionize melanoma diagnosis. It will not only save lives, but also reduce the anxiety caused by false results. While the European market is our top priority for dermalyzers, the recently approved AI and FDA powered devices for skin cancer detection also have clear implications for the company. We have established regulatory pathways and are currently accelerating our plans to enter the U.S. market.”

For more information, please contact us below.

Christopher Ekström, AI Medical Technology CEO

Email: [email protected]

Mobile: +46704 02 71 01

For more information, see www.aimedtech.com and https://www.linkedin.com/company/aimedicaltechnology/

Photo – https://mma.prnewswire.com/media/2355078/Dermalyser.jpg
Photo – https://mma.prnewswire.com/media/2355079/CEO_Christoffer_Ekstr_m4.jpg
Logo – https://mma.prnewswire.com/media/2355080/AMT_Logo.jpg

SOURCE AI Medical Technology



Source link